Published in Bioorg Med Chem Lett on May 05, 1998
(E)-3-(2,6-Dichloro-phen-yl)-1-(4-methoxy-phen-yl)prop-2-en-1-one. Acta Crystallogr Sect E Struct Rep Online (2009) 1.44
Emerging role of Garcinol, the antioxidant chalcone from Garcinia indica Choisy and its synthetic analogs. J Hematol Oncol (2009) 1.12
Design, synthesis, and biological evaluations of 2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoline analogs of combretastatin-A4. J Med Chem (2010) 1.07
Dietary chalcones with chemopreventive and chemotherapeutic potential. Genes Nutr (2011) 1.00
Novel chalcone derivatives as potent Nrf2 activators in mice and human lung epithelial cells. J Med Chem (2011) 0.99
Hybrid alpha-bromoacryloylamido chalcones. Design, synthesis and biological evaluation. Bioorg Med Chem Lett (2009) 0.86
Design, synthesis, and biological evaluation of novel pyridine-bridged analogues of combretastatin-A4 as anticancer agents. J Med Chem (2014) 0.84
Molecular targeted approaches to cancer therapy and prevention using chalcones. Curr Cancer Drug Targets (2014) 0.83
A boronic acid chalcone analog of combretastatin A-4 as a potent anti-proliferation agent. Bioorg Med Chem (2009) 0.83
IPP51, a chalcone acting as a microtubule inhibitor with in vivo antitumor activity against bladder carcinoma. Oncotarget (2015) 0.80
Cytotoxic 3,4,5-trimethoxychalcones as mitotic arresters and cell migration inhibitors. Eur J Med Chem (2013) 0.77
Docking, synthesis and antiproliferative activity of N-acylhydrazone derivatives designed as combretastatin A4 analogues. PLoS One (2014) 0.77
Synthesis, electronic, and spectral properties of novel geranylated chalcone derivatives: a theoretical and experimental study. J Mol Model (2016) 0.76
Chalcone-imidazolone conjugates induce apoptosis through DNA damage pathway by affecting telomeres. Cancer Cell Int (2011) 0.76
3-Aroyl-1,4-diarylpyrroles Inhibit Chronic Myeloid Leukemia Cell Growth through an Interaction with Tubulin. ACS Med Chem Lett (2017) 0.75
Selected novel 5'-amino-2'-hydroxy-1, 3-diaryl-2-propen-1-ones arrest cell cycle of HCT-116 in G0/G1 phase. EXCLI J (2016) 0.75
Crystal structure of (E)-3-(3,4-di-meth-oxy-phen-yl)-1-(1-hy-droxy-naphthalen-2-yl)prop-2-en-1-one. Acta Crystallogr E Crystallogr Commun (2015) 0.75
The Plant-Derived Chalcone 2,2',5'-Trihydroxychalcone Provides Neuroprotection against Toll-Like Receptor 4 Triggered Inflammation in Microglia. Oxid Med Cell Longev (2015) 0.75
Nucleolar localization of early tRNA processing. Genes Dev (1998) 2.78
Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev (1998) 2.12
War Neurosis: A Year in a Neuropathic Hospital-I. Br Med J (1942) 1.98
Women with a history of gestational diabetes of European and South Asian origin are shorter than women with normal glucose tolerance in pregnancy. Diabet Med (2000) 1.67
In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer (1999) 1.47
Linked parallel synthesis and MTT bioassay screening of substituted chalcones. J Comb Chem (2001) 1.38
Precision top-quark mass measurement at CDF. Phys Rev Lett (2012) 1.30
Questionnaire-based measures are valid for the identification of rural households with hunger and food insecurity. J Nutr (1997) 1.25
Implications of new diagnostic criteria for abnormal glucose homeostasis in women with previous gestational diabetes. Diabetes Care (1999) 1.23
Measurement of the cross section for prompt isolated diphoton production using the full CDF run II data sample. Phys Rev Lett (2013) 1.22
The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane. Cell Death Differ (2010) 1.20
A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. Br J Cancer (1995) 1.19
The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Br J Cancer (1995) 1.19
Measurement of the WW + WZ production cross section using the lepton + jets final state at CDF II. Phys Rev Lett (2010) 1.12
First observation of the decay Bs0-->Ds-Ds+ and measurement of its branching ratio. Phys Rev Lett (2008) 1.11
War Neurosis: A Year in a Neuropathic Hospital-II. Br Med J (1942) 1.10
Novel syntheses of cis and trans isomers of combretastatin A-4. J Org Chem (2001) 1.10
Evidence for a particle produced in association with weak bosons and decaying to a bottom-antibottom quark pair in higgs boson searches at the tevatron. Phys Rev Lett (2012) 1.08
Precise measurement of the W-boson mass with the CDF II detector. Phys Rev Lett (2012) 1.06
A proposed mechanism of resistance to cyclophosphamide and phosphoramide mustard in a Yoshida cell line in vitro. Cancer Chemother Pharmacol (1986) 1.06
Direct measurement of the W production charge asymmetry in pp collisions at square root s=1.96 TeV. Phys Rev Lett (2009) 1.04
Search for long-lived massive charged particles in 1.96 TeV pp collisions. Phys Rev Lett (2009) 1.03
Bioactivity and molecular modelling of diphenylsulfides and diphenylselenides. Bioorg Med Chem (1993) 1.03
Polygalacturonase, PGIP and oligogalacturonides in cell-cell communication. Biochem Soc Trans (1994) 1.02
Hunger and food insecurity in the elderly: its nature and measurement. J Aging Health (1998) 1.00
Comparative studies of the uptake of daunorubicin in sensitive and resistant P388 cell lines by flow cytometry and biochemical extraction procedures. Cancer Chemother Pharmacol (1983) 0.99
Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients. Cancer Res (2000) 0.98
Mice with skin-specific DNA repair gene (Ercc1) inactivation are hypersensitive to ultraviolet irradiation-induced skin cancer and show more rapid actinic progression. Oncogene (2006) 0.98
The impact of ethnicity on glucose regulation and the metabolic syndrome following gestational diabetes. Diabetologia (2005) 0.98
Search for large extra dimensions in final states containing one photon or jet and large missing transverse energy produced in pp collisions at square root[s]=1.96 TeV. Phys Rev Lett (2008) 0.97
Polarizations of J/psi and psi(2S) mesons produced in pp collisions at square root s = 1.96 TeV. Phys Rev Lett (2007) 0.96
Cytotoxic Michael-type amine adducts of alpha-methylene lactones alantolactone and isoalantolactone. Bioorg Med Chem Lett (2001) 0.94
Search for a fermiophobic Higgs boson decaying into diphotons in pp[over] collisions at sqrt[s] = 1.96 TeV. Phys Rev Lett (2009) 0.92
Antimitotic and cell growth inhibitory properties of combretastatin A-4-like ethers. Bioorg Med Chem Lett (2001) 0.92
The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo. Biochem Pharmacol (1989) 0.92
The effect of vinca alkaloids in enhancing the sensitivity of a methotrexate-resistant (L1210/R7A) line, studied by flow cytometric and chromosome number analysis. Cancer Chemother Pharmacol (1984) 0.91
First measurement of the b-jet cross section in events with a W boson in pp collisions at square root(s) = 1.96 TeV. Phys Rev Lett (2010) 0.91
14 beta-O-cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity. J Med Chem (2009) 0.90
Measurements of the angular distributions in the decays B→K(*)μ(+)μ(-) at CDF. Phys Rev Lett (2012) 0.88
The role of the fetus in the formation of amniotic fluid. J Obstet Gynaecol Br Commonw (1972) 0.88
p53 and related proteins in epithelial ovarian cancer. Eur J Cancer (2000) 0.88
Synthesis and anticancer activities of 4-oxobenzopyrano[2,3-d]pyrimidines. Anticancer Drugs (1999) 0.87
Position of the American Dietetic Association: domestic food and nutrition security. J Am Diet Assoc (1998) 0.87
Positron emission tomography of murine liver metastases and the effects of treatment by combretastatin A-4. Eur J Nucl Med (1999) 0.87
Search for top-quark production via flavor-changing neutral currents in W+1 jet events at CDF. Phys Rev Lett (2009) 0.87
Inclusive search for squark and gluino production in pp[over ] collisions at sqrt[s]=1.96 TeV. Phys Rev Lett (2009) 0.87
Stress, anxiety, depression, and physical illness in college students. J Genet Psychol (1994) 0.87
A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma. Br J Cancer (2001) 0.86
Search for the flavor-changing neutral-current decay t-->Zq in pp collisions at sqrt[s] = 1.96 TeV. Phys Rev Lett (2008) 0.86
The interaction of chalcones with tubulin. Anticancer Drug Des (2000) 0.86
Lymphocyte proliferation responses after exercise in men: fitness, intensity, and duration effects. J Appl Physiol (1985) (1991) 0.85
Search for the standard model Higgs Boson produced in association with top quarks using the full CDF data set. Phys Rev Lett (2012) 0.85
Isoflavones inhibit intestinal epithelial cell proliferation and induce apoptosis in vitro. Br J Cancer (1999) 0.85
Search for dark matter in events with one jet and missing transverse energy in pp¯ collisions at √s=1.96 TeV. Phys Rev Lett (2012) 0.84
Measurement of the forward-backward asymmetry in the B→K*μ(+)μ(-) decay and first observation of the B(s)0→ϕμ(+)μ(-) decay. Phys Rev Lett (2011) 0.83
Search for Higgs bosons predicted in two-Higgs-doublet models via decays to tau lepton pairs in 1.96 TeV pp collisions. Phys Rev Lett (2009) 0.83
Analogues of Y27632 increase gap junction communication and suppress the formation of transformed NIH3T3 colonies. Br J Cancer (2009) 0.83
Glutathione S-transferase activity and isoenzyme distribution in ovarian tumour biopsies taken before or after cytotoxic chemotherapy. Br J Cancer (1992) 0.83
O6-Benzylguanine potentiates BCNU but not busulfan toxicity in hematopoietic stem cells. Exp Hematol (2001) 0.83
Search for supersymmetry in pp collisions at sqrt[s]=1.96 TeV Using the trilepton signature for chargino-neutralino production. Phys Rev Lett (2008) 0.83
Combination of Tevatron searches for the standard model Higgs boson in the W+W- decay mode. Phys Rev Lett (2010) 0.83
Phase II study of oral capecitabine in patients with hormone-refractory prostate cancer. Prostate Cancer Prostatic Dis (2005) 0.83
The role of metallothionein, glutathione, glutathione S-transferases and DNA repair in resistance to platinum drugs in a series of L1210 cell lines made resistant to anticancer platinum agents. Biochem Pharmacol (1993) 0.82
Forward-backward asymmetry in top-quark production in pp[over] collisions at sqrt[s]=1.96 TeV. Phys Rev Lett (2008) 0.82
Search for B(s)(0) → μ+ μ- and B(0) → μ+ μ- decays with CDF II. Phys Rev Lett (2011) 0.82
Metallothionein levels in ovarian tumours before and after chemotherapy. Br J Cancer (1991) 0.82
Search for the production of narrow tb[over] resonances in 1.9 fb;{-1} of pp[over] collisions at sqrt[s] = 1.96 TeV. Phys Rev Lett (2009) 0.82
Isolation of paeonol from Arisaema erubescens. Planta Med (1995) 0.82
Complex conserved organization of the mammalian leukemia inhibitory factor gene: regulated expression of intracellular and extracellular cytokines. J Immunol (1999) 0.82
Observation of the baryonic flavor-changing neutral current decay Λb(0)→Λμ+μ-. Phys Rev Lett (2011) 0.81
Development and validation of a sensitive solid-phase extraction and high-performance liquid chromatography assay for the novel antitumour agent CT2584 in human plasma. J Chromatogr B Biomed Sci Appl (1999) 0.81
Human germ cell tumor cell lines express novel leukemia inhibitory factor transcripts encoding differentially localized proteins. Exp Cell Res (1999) 0.81
Observation of electroweak single top-quark production. Phys Rev Lett (2009) 0.80
Inhibition of human tumor cell induced platelet aggregation by antibodies to platelet glycoproteins Ib and IIb/IIIa. Proc Soc Exp Biol Med (1987) 0.80
A simulation of hand impairments: effects on upper extremity function and implications toward medical impairment rating and disability determination. Arch Phys Med Rehabil (1997) 0.80
Clinical efficacy of capecitabine as first-line chemotherapy in metastatic breast cancer--how low can you go? Breast (2007) 0.80
High-performance liquid chromatographic assay for the novel antitumor drug, bryostatin-1, incorporating a serum extraction technique. J Chromatogr B Biomed Sci Appl (1998) 0.80
Novel nonpeptidic inhibitors of peptide deformylase. Arch Biochem Biophys (2000) 0.79
The effects of growth hormone replacement therapy on overnight metabolic fuels in hypopituitary patients. Clin Endocrinol (Oxf) (2000) 0.79
Isolation of E-1-(4'-Hydroxyphenyl)-but-1-en-3-one from Scutellaria barbata. Planta Med (1996) 0.79